Akumin (NASDAQ:AKU – Get Rating) is one of 46 publicly-traded companies in the "Medical laboratories" industry, but how does it compare to its competitors? We will compare Akumin to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, valuation, institutional ownership and dividends.
Institutional and Insider Ownership
25.1% of Akumin shares are held by institutional investors. Comparatively, 53.5% of shares of all "Medical laboratories" companies are held by institutional investors. 17.0% of shares of all "Medical laboratories" companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Get Akumin alerts:Valuation and Earnings
This table compares Akumin and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Akumin | $421.08 million | -$43.29 million | -1.60 |
| Akumin Competitors | $1.04 billion | $57.33 million | -0.06 |
Volatility & Risk
Akumin has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Akumin's competitors have a beta of -1.65, meaning that their average share price is 265% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Akumin and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akumin | 2 | 0 | 0 | 0 | 1.00 |
| Akumin Competitors | 136 | 719 | 1614 | 30 | 2.62 |
Akumin currently has a consensus target price of $0.63, indicating a potential downside of 63.45%. As a group, "Medical laboratories" companies have a potential upside of 100.90%. Given Akumin's competitors stronger consensus rating and higher probable upside, analysts clearly believe Akumin has less favorable growth aspects than its competitors.
Profitability
This table compares Akumin and its competitors' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akumin | -14.16% | -29.00% | -3.87% |
| Akumin Competitors | -1,501.07% | -52.65% | -22.32% |
Summary
Akumin competitors beat Akumin on 9 of the 13 factors compared.
Akumin Company Profile
(Get Rating)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.